 Cory Dunnick
Concepts (331)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Allergic Contact | 43 | 2025 | 72 | 12.350 |
Why?
| | Dermatology | 29 | 2025 | 128 | 6.850 |
Why?
| | Patch Tests | 36 | 2025 | 57 | 6.090 |
Why?
| | Allergens | 31 | 2025 | 384 | 4.040 |
Why?
| | Dermatitis, Occupational | 11 | 2024 | 16 | 3.980 |
Why?
| | Skin Diseases | 11 | 2021 | 149 | 2.170 |
Why?
| | North America | 26 | 2025 | 310 | 2.060 |
Why?
| | Dermatitis, Irritant | 4 | 2021 | 9 | 1.600 |
Why?
| | Sunscreening Agents | 6 | 2024 | 25 | 1.420 |
Why?
| | Soaps | 3 | 2020 | 10 | 1.320 |
Why?
| | Education, Medical, Undergraduate | 4 | 2019 | 206 | 1.280 |
Why?
| | Skin Neoplasms | 12 | 2024 | 847 | 1.230 |
Why?
| | Melanoma | 10 | 2024 | 761 | 1.190 |
Why?
| | Dermatitis, Contact | 2 | 2020 | 18 | 1.140 |
Why?
| | Dermatologic Agents | 3 | 2024 | 68 | 1.110 |
Why?
| | Students, Medical | 4 | 2021 | 375 | 1.010 |
Why?
| | Pigmentation Disorders | 2 | 2024 | 8 | 0.980 |
Why?
| | Dermatitis, Toxicodendron | 1 | 2026 | 1 | 0.980 |
Why?
| | Curriculum | 5 | 2019 | 1059 | 0.970 |
Why?
| | Schools, Medical | 2 | 2019 | 156 | 0.970 |
Why?
| | Cosmetics | 2 | 2022 | 8 | 0.920 |
Why?
| | Desensitization, Immunologic | 1 | 2026 | 89 | 0.900 |
Why?
| | Dermatitis, Photoallergic | 1 | 2024 | 3 | 0.860 |
Why?
| | Irritants | 2 | 2021 | 38 | 0.850 |
Why?
| | Surface-Active Agents | 2 | 2022 | 92 | 0.840 |
Why?
| | Hand Dermatoses | 2 | 2021 | 7 | 0.820 |
Why?
| | Alopecia Areata | 2 | 2021 | 13 | 0.810 |
Why?
| | Music | 2 | 2021 | 48 | 0.810 |
Why?
| | Leprosy | 3 | 2020 | 25 | 0.810 |
Why?
| | Telemedicine | 7 | 2020 | 945 | 0.810 |
Why?
| | Nickel | 5 | 2025 | 64 | 0.780 |
Why?
| | Humans | 107 | 2026 | 144759 | 0.770 |
Why?
| | Anti-Infective Agents, Local | 2 | 2020 | 40 | 0.760 |
Why?
| | Hair Preparations | 1 | 2021 | 2 | 0.700 |
Why?
| | Retrospective Studies | 32 | 2024 | 17066 | 0.700 |
Why?
| | Thiazoles | 5 | 2025 | 135 | 0.670 |
Why?
| | Occupations | 1 | 2021 | 51 | 0.670 |
Why?
| | Skin Pigmentation | 1 | 2021 | 48 | 0.670 |
Why?
| | Eczema | 1 | 2021 | 66 | 0.660 |
Why?
| | Psoriasis | 5 | 2021 | 112 | 0.650 |
Why?
| | Hand Hygiene | 1 | 2020 | 9 | 0.650 |
Why?
| | Facial Dermatoses | 4 | 2021 | 17 | 0.640 |
Why?
| | Carbanilides | 1 | 2019 | 4 | 0.620 |
Why?
| | Triclosan | 1 | 2019 | 9 | 0.620 |
Why?
| | Severity of Illness Index | 5 | 2018 | 2925 | 0.610 |
Why?
| | Education, Medical | 2 | 2019 | 274 | 0.590 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1185 | 0.550 |
Why?
| | Cold Injury | 1 | 2017 | 1 | 0.540 |
Why?
| | Mountaineering | 1 | 2017 | 36 | 0.530 |
Why?
| | Global Health | 9 | 2020 | 401 | 0.520 |
Why?
| | Weather | 1 | 2017 | 43 | 0.520 |
Why?
| | Internship and Residency | 8 | 2018 | 1257 | 0.520 |
Why?
| | Patient Satisfaction | 3 | 2018 | 704 | 0.500 |
Why?
| | Public Opinion | 1 | 2016 | 60 | 0.480 |
Why?
| | United States | 26 | 2024 | 15966 | 0.470 |
Why?
| | Keloid | 1 | 2015 | 8 | 0.460 |
Why?
| | Ultraviolet Rays | 2 | 2017 | 388 | 0.460 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2015 | 21 | 0.450 |
Why?
| | Physical Examination | 1 | 2016 | 239 | 0.450 |
Why?
| | Career Choice | 2 | 2016 | 237 | 0.440 |
Why?
| | Prevalence | 10 | 2024 | 2834 | 0.430 |
Why?
| | Quality of Life | 3 | 2020 | 3185 | 0.430 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 321 | 0.420 |
Why?
| | Petrolatum | 3 | 2023 | 3 | 0.410 |
Why?
| | Electronic Prescribing | 1 | 2013 | 3 | 0.410 |
Why?
| | Clinical Competence | 4 | 2019 | 1244 | 0.400 |
Why?
| | Female | 37 | 2025 | 78271 | 0.380 |
Why?
| | Male | 34 | 2025 | 72315 | 0.380 |
Why?
| | Alopecia | 2 | 2023 | 37 | 0.370 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1560 | 0.360 |
Why?
| | Cannabinoids | 3 | 2020 | 182 | 0.360 |
Why?
| | Societies, Medical | 5 | 2020 | 887 | 0.360 |
Why?
| | Biomedical Research | 4 | 2025 | 710 | 0.360 |
Why?
| | Piperidines | 2 | 2024 | 217 | 0.350 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1356 | 0.350 |
Why?
| | Dermatitis, Seborrheic | 2 | 2021 | 5 | 0.350 |
Why?
| | Young Adult | 13 | 2025 | 14105 | 0.340 |
Why?
| | Internet | 5 | 2018 | 699 | 0.340 |
Why?
| | Adult | 25 | 2025 | 40449 | 0.320 |
Why?
| | Drug Industry | 3 | 2019 | 49 | 0.320 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 557 | 0.300 |
Why?
| | Pyrimidines | 2 | 2024 | 532 | 0.300 |
Why?
| | Consumer Product Safety | 1 | 2009 | 32 | 0.300 |
Why?
| | Cross-Sectional Studies | 11 | 2024 | 5868 | 0.290 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1489 | 0.290 |
Why?
| | United States Food and Drug Administration | 2 | 2019 | 203 | 0.280 |
Why?
| | Skin | 3 | 2021 | 755 | 0.280 |
Why?
| | Conflict of Interest | 2 | 2019 | 52 | 0.280 |
Why?
| | Quality Improvement | 2 | 2016 | 1289 | 0.270 |
Why?
| | Publishing | 2 | 2019 | 114 | 0.260 |
Why?
| | Adhesives | 2 | 2024 | 15 | 0.250 |
Why?
| | Administration, Topical | 2 | 2024 | 150 | 0.250 |
Why?
| | Adolescent | 10 | 2024 | 22428 | 0.250 |
Why?
| | Middle Aged | 16 | 2025 | 35875 | 0.250 |
Why?
| | Child | 9 | 2024 | 22633 | 0.230 |
Why?
| | Administration, Oral | 2 | 2026 | 847 | 0.230 |
Why?
| | Incidence | 4 | 2020 | 2879 | 0.230 |
Why?
| | Trace Elements | 1 | 2006 | 52 | 0.230 |
Why?
| | Electronic Health Records | 1 | 2013 | 1173 | 0.220 |
Why?
| | Glucosides | 2 | 2022 | 55 | 0.220 |
Why?
| | Colorado | 5 | 2025 | 4564 | 0.220 |
Why?
| | Mentha piperita | 1 | 2024 | 1 | 0.220 |
Why?
| | Photosensitivity Disorders | 1 | 2024 | 8 | 0.220 |
Why?
| | Laboratories | 1 | 2025 | 109 | 0.220 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 28 | 0.210 |
Why?
| | Plant Oils | 1 | 2024 | 31 | 0.210 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 125 | 0.210 |
Why?
| | Pyrroles | 2 | 2024 | 217 | 0.210 |
Why?
| | Construction Industry | 1 | 2024 | 18 | 0.210 |
Why?
| | Chlorhexidine | 2 | 2023 | 23 | 0.200 |
Why?
| | Health Education | 2 | 2017 | 358 | 0.200 |
Why?
| | Hair Dyes | 1 | 2023 | 3 | 0.200 |
Why?
| | Health Personnel | 2 | 2020 | 748 | 0.200 |
Why?
| | Periodicals as Topic | 2 | 2018 | 203 | 0.200 |
Why?
| | Cost of Illness | 5 | 2020 | 321 | 0.190 |
Why?
| | Drugs, Generic | 1 | 2023 | 27 | 0.190 |
Why?
| | Sunburn | 2 | 2019 | 26 | 0.180 |
Why?
| | Plant Extracts | 2 | 2021 | 187 | 0.180 |
Why?
| | Aged | 10 | 2025 | 25913 | 0.180 |
Why?
| | Resins, Plant | 1 | 2021 | 5 | 0.180 |
Why?
| | Dental Implants | 1 | 2022 | 10 | 0.180 |
Why?
| | Contact Lens Solutions | 1 | 2021 | 1 | 0.180 |
Why?
| | Dermatitis, Phototoxic | 1 | 2021 | 3 | 0.180 |
Why?
| | Palmitic Acids | 1 | 2021 | 10 | 0.180 |
Why?
| | Ethanolamines | 1 | 2021 | 14 | 0.180 |
Why?
| | Ammonium Sulfate | 1 | 2021 | 13 | 0.180 |
Why?
| | Office Visits | 2 | 2018 | 90 | 0.170 |
Why?
| | Dental Materials | 1 | 2022 | 56 | 0.170 |
Why?
| | Aircraft | 1 | 2021 | 23 | 0.170 |
Why?
| | Clothing | 1 | 2021 | 23 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2024 | 11679 | 0.170 |
Why?
| | Coloring Agents | 1 | 2021 | 93 | 0.170 |
Why?
| | Hydrogen Peroxide | 1 | 2023 | 336 | 0.170 |
Why?
| | Oxidants | 1 | 2021 | 103 | 0.170 |
Why?
| | Ophthalmic Solutions | 1 | 2021 | 79 | 0.170 |
Why?
| | Occupational Exposure | 2 | 2024 | 354 | 0.170 |
Why?
| | Amides | 1 | 2021 | 101 | 0.170 |
Why?
| | Registries | 3 | 2021 | 2385 | 0.160 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 57 | 0.160 |
Why?
| | Subcutaneous Tissue | 1 | 2020 | 26 | 0.160 |
Why?
| | Age Distribution | 2 | 2019 | 403 | 0.160 |
Why?
| | Endemic Diseases | 1 | 2020 | 33 | 0.160 |
Why?
| | Benzethonium | 1 | 2019 | 1 | 0.160 |
Why?
| | Physicians | 2 | 2019 | 939 | 0.160 |
Why?
| | Masks | 1 | 2020 | 70 | 0.150 |
Why?
| | Xylenes | 1 | 2019 | 8 | 0.150 |
Why?
| | Health Care Costs | 2 | 2015 | 427 | 0.150 |
Why?
| | Communicable Disease Control | 1 | 2020 | 86 | 0.150 |
Why?
| | Benzalkonium Compounds | 1 | 2019 | 15 | 0.150 |
Why?
| | Marketing | 1 | 2019 | 24 | 0.150 |
Why?
| | Developed Countries | 2 | 2017 | 38 | 0.150 |
Why?
| | Chemoprevention | 2 | 2016 | 90 | 0.150 |
Why?
| | Consultants | 1 | 2019 | 12 | 0.150 |
Why?
| | Child, Preschool | 4 | 2024 | 11787 | 0.150 |
Why?
| | Cannabidiol | 1 | 2021 | 136 | 0.150 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 257 | 0.150 |
Why?
| | Bibliometrics | 1 | 2019 | 63 | 0.140 |
Why?
| | Drug Approval | 1 | 2019 | 89 | 0.140 |
Why?
| | Authorship | 1 | 2019 | 49 | 0.140 |
Why?
| | Financial Support | 1 | 2018 | 17 | 0.140 |
Why?
| | Quality of Health Care | 2 | 2013 | 691 | 0.140 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 5 | 0.140 |
Why?
| | Primary Prevention | 1 | 2020 | 220 | 0.140 |
Why?
| | Consumer Health Information | 1 | 2018 | 49 | 0.140 |
Why?
| | Water | 1 | 2021 | 469 | 0.140 |
Why?
| | Hyperpigmentation | 1 | 2018 | 27 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2019 | 221 | 0.130 |
Why?
| | Down Syndrome | 1 | 2024 | 534 | 0.130 |
Why?
| | Video Recording | 1 | 2018 | 212 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Environmental Monitoring | 1 | 2020 | 377 | 0.130 |
Why?
| | Developing Countries | 2 | 2017 | 318 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 641 | 0.130 |
Why?
| | Social Networking | 1 | 2017 | 37 | 0.130 |
Why?
| | Outpatients | 1 | 2020 | 442 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2020 | 6048 | 0.120 |
Why?
| | Photography | 1 | 2017 | 115 | 0.120 |
Why?
| | Travel | 1 | 2017 | 136 | 0.120 |
Why?
| | Substance P | 1 | 1996 | 39 | 0.120 |
Why?
| | Sex Factors | 2 | 2020 | 2112 | 0.120 |
Why?
| | Micronutrients | 1 | 2016 | 96 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2020 | 1095 | 0.120 |
Why?
| | Age Factors | 1 | 2023 | 3333 | 0.120 |
Why?
| | Reward | 1 | 2018 | 247 | 0.120 |
Why?
| | Access to Information | 1 | 2016 | 48 | 0.120 |
Why?
| | Ear Auricle | 1 | 2015 | 14 | 0.110 |
Why?
| | Scalp | 1 | 2015 | 37 | 0.110 |
Why?
| | Keratinocytes | 1 | 2016 | 248 | 0.110 |
Why?
| | Community Health Services | 1 | 2017 | 233 | 0.110 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 245 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Mobile Applications | 1 | 2018 | 196 | 0.110 |
Why?
| | Neovascularization, Physiologic | 1 | 1996 | 194 | 0.110 |
Why?
| | Research Support as Topic | 1 | 2015 | 80 | 0.110 |
Why?
| | Shoulder | 1 | 2015 | 105 | 0.110 |
Why?
| | National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) | 1 | 2014 | 1 | 0.110 |
Why?
| | Carcinoma | 1 | 2016 | 228 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2015 | 222 | 0.110 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2015 | 140 | 0.110 |
Why?
| | Chlorpromazine | 1 | 2014 | 5 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 645 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2017 | 547 | 0.110 |
Why?
| | Corneal Opacity | 1 | 2014 | 8 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 509 | 0.100 |
Why?
| | Parkinson Disease | 1 | 2020 | 600 | 0.100 |
Why?
| | Financing, Government | 1 | 2014 | 53 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2018 | 600 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 338 | 0.100 |
Why?
| | Wound Healing | 1 | 1996 | 351 | 0.100 |
Why?
| | Universities | 1 | 2016 | 452 | 0.100 |
Why?
| | Altitude | 1 | 2017 | 473 | 0.100 |
Why?
| | Research Report | 1 | 2013 | 87 | 0.100 |
Why?
| | Cornea | 1 | 2014 | 155 | 0.090 |
Why?
| | Social Support | 1 | 2017 | 652 | 0.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 439 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3409 | 0.090 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 213 | 0.090 |
Why?
| | Acne Vulgaris | 1 | 2011 | 25 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1694 | 0.090 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 463 | 0.090 |
Why?
| | Cobalt | 2 | 2025 | 53 | 0.090 |
Why?
| | Perfume | 2 | 2024 | 5 | 0.090 |
Why?
| | Burns | 1 | 1996 | 377 | 0.090 |
Why?
| | Infant | 3 | 2024 | 10034 | 0.080 |
Why?
| | Quality-Adjusted Life Years | 3 | 2017 | 121 | 0.080 |
Why?
| | Social Media | 1 | 2014 | 171 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1720 | 0.080 |
Why?
| | Databases, Factual | 3 | 2020 | 1486 | 0.070 |
Why?
| | Needs Assessment | 1 | 2011 | 404 | 0.070 |
Why?
| | Information Dissemination | 1 | 2010 | 223 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 2310 | 0.070 |
Why?
| | Risk Factors | 4 | 2021 | 10779 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2010 | 780 | 0.060 |
Why?
| | Minnesota | 1 | 2025 | 169 | 0.060 |
Why?
| | Disability Evaluation | 2 | 2017 | 310 | 0.050 |
Why?
| | Phenylenediamines | 1 | 2023 | 12 | 0.050 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2023 | 26 | 0.050 |
Why?
| | Benzophenones | 1 | 2023 | 16 | 0.050 |
Why?
| | Canada | 1 | 2024 | 428 | 0.050 |
Why?
| | Interferon-beta | 1 | 2023 | 92 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2025 | 465 | 0.050 |
Why?
| | Lanolin | 1 | 2022 | 1 | 0.050 |
Why?
| | Dentistry | 1 | 2022 | 9 | 0.050 |
Why?
| | Europe | 1 | 2023 | 412 | 0.040 |
Why?
| | Chorioallantoic Membrane | 1 | 2021 | 3 | 0.040 |
Why?
| | Spider Bites | 1 | 2001 | 7 | 0.040 |
Why?
| | Patient-Centered Care | 2 | 2018 | 544 | 0.040 |
Why?
| | Neck | 1 | 2021 | 108 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 312 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1075 | 0.040 |
Why?
| | Global Burden of Disease | 1 | 2020 | 23 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2021 | 1047 | 0.040 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 96 | 0.040 |
Why?
| | Prognosis | 2 | 2018 | 4282 | 0.040 |
Why?
| | Sunbathing | 1 | 2018 | 16 | 0.040 |
Why?
| | Manufacturing Industry | 1 | 2018 | 6 | 0.040 |
Why?
| | Autoimmunity | 1 | 2024 | 926 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 196 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 35 | 0.040 |
Why?
| | Dermatologists | 1 | 2018 | 7 | 0.040 |
Why?
| | Aerosols | 1 | 2019 | 186 | 0.030 |
Why?
| | Transportation | 1 | 2018 | 54 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2018 | 333 | 0.030 |
Why?
| | Thorax | 1 | 2018 | 50 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 7173 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2018 | 139 | 0.030 |
Why?
| | China | 1 | 2018 | 269 | 0.030 |
Why?
| | Polypodium | 1 | 2016 | 1 | 0.030 |
Why?
| | Autoantibodies | 1 | 2024 | 1501 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 12 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1047 | 0.030 |
Why?
| | Smartphone | 1 | 2018 | 102 | 0.030 |
Why?
| | Balsams | 1 | 2016 | 2 | 0.030 |
Why?
| | Patient Care | 1 | 2018 | 118 | 0.030 |
Why?
| | Bacitracin | 1 | 2016 | 5 | 0.030 |
Why?
| | Cytokines | 1 | 2024 | 2061 | 0.030 |
Why?
| | Research Design | 1 | 2023 | 1135 | 0.030 |
Why?
| | Neomycin | 1 | 2016 | 7 | 0.030 |
Why?
| | Propylene Glycol | 1 | 2016 | 9 | 0.030 |
Why?
| | p-Aminohippuric Acid | 1 | 1996 | 5 | 0.030 |
Why?
| | Culture Techniques | 1 | 1996 | 67 | 0.030 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 1996 | 14 | 0.030 |
Why?
| | Ketoglutaric Acids | 1 | 1996 | 23 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1135 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2017 | 101 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 65 | 0.030 |
Why?
| | Waiting Lists | 1 | 2018 | 263 | 0.030 |
Why?
| | Formaldehyde | 1 | 2016 | 66 | 0.030 |
Why?
| | Neuropeptides | 1 | 1996 | 77 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 854 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1658 | 0.030 |
Why?
| | Gold | 1 | 2016 | 115 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2020 | 428 | 0.030 |
Why?
| | Personnel Selection | 1 | 2016 | 93 | 0.030 |
Why?
| | Syphilis | 1 | 2014 | 33 | 0.030 |
Why?
| | Measles | 1 | 2014 | 46 | 0.030 |
Why?
| | Chickenpox | 1 | 2014 | 81 | 0.030 |
Why?
| | Leadership | 1 | 2018 | 408 | 0.020 |
Why?
| | Dengue | 1 | 2014 | 89 | 0.020 |
Why?
| | Health Communication | 1 | 2014 | 54 | 0.020 |
Why?
| | Patient Advocacy | 1 | 2014 | 73 | 0.020 |
Why?
| | Faculty, Medical | 1 | 2016 | 302 | 0.020 |
Why?
| | Health Status | 1 | 2018 | 836 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2117 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1716 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1813 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2015 | 377 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 539 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 489 | 0.020 |
Why?
| | Schizophrenia | 1 | 2014 | 446 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1098 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1907 | 0.020 |
Why?
| | Medicaid | 1 | 2013 | 461 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3671 | 0.020 |
Why?
| | Kidney | 1 | 1996 | 1495 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1985 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 886 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 7190 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7990 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8265 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2016 | 6429 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18339 | 0.010 |
Why?
| | Animals | 2 | 2017 | 38058 | 0.010 |
Why?
| | Ouabain | 1 | 1996 | 19 | 0.010 |
Why?
| | Glutarates | 1 | 1996 | 11 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1996 | 268 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2027 | 0.010 |
Why?
| | Rats | 1 | 1996 | 5597 | 0.000 |
Why?
|
|
Dunnick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|